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Essentially the same general radiobiological considerations apply to 
kilovoltage as to megavoltage x rays i.e. cell killing is adequately 
described by the linear-quadratic model, and for (most) tumour 
types we expect a higher α/β than for normal tissues thus making 
fractionation theoretically advantageous. However, given the ex-
tremely rapid fall-off of dose with depth, and the fact that today only 
superficial tumours are treated with kilovoltage beams, the dose to 
any underlying normal tissues will inevitably be very low and may 
therefore pose a negligible complication risk. This enables large 
fractions to be used. 
Megavoltage therapy was already well established when computer 
planning systems first came on the scene in the 1970s. Naturally all 
the effort went into developing algorithms for computing dose in 
patients from such beams and consequently no treatment planning 
systems model kilovoltage beams. The very large amount of (photon) 
scatter, which gives rise to a build-up of dose at small depths, would 
pose quite a challenge for algorithm developers, though secondary 
electron transport can be ignored as the low initial electron ener-
gies result in largely sub-millimetre ranges in tissue. We have created 
a simple 250 kV x-ray plan for a lung tumour using the GEANT Monte-
Carlo code in order to compare the DVHs to those derived from a 
megavoltage plan. For one particular NSCLC patient, treated with 6 
MV x rays, this comparion has yielded 0% TCP for the kV plan for the 
same 9.5% lung pneumonitis NTCP as for the MV plan. Increasing the 
NTCP to 15% for both plans (i.e. by winding up the MUs) has yielded 
TCPs of 94.6% for the MV plan against 1.9% for the kV plan. However, 
this was for a realtively large tumour.   
It can be noted that kilovoltage therapy is undergoing a renais-
sance through 50 kV 'Papillon' contact therapy for rectal tumours.     
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Purpose: Accuracy in patients positioning with novel irradiation 
techniques, which allow tight conformation of dose distribution, is of 
great interest in image guided radiotherapy (IGRT) era.  
Material and methods: Several studies have examined the relevance 
and the magnitude of rotational set up errors, using portal image 
registration, serial CT scans or recently employing kilovoltage cone-
beam CT (CBCT). They demonstrated that in prostate, head & neck 
and thoracic cancer, rotational errors are small in magnitude but 
statistically significant and that their magnitude is not correlated with 
the magnitude of the translational set up errors. Morevover several 
authors demonstrated that online correction of rotation can improve 
target coverage because rotational shift could have an impact on dose 
distribution, varying according to treatment site and to radiation 
techniques. Therefore an approach to improving accuracy of patient 
positioning is to develop devices that permit couch movement with 
6°of freedom (6DOF). In our centre the ProturaTM Robotic Patient 
Positioning System (CIVCO Medical Solution) was installed onto a 
Linear accelerator (Varian Medical System). We started a study to 
evaluate therelevance of rotational shift in IGRT and to validate the 
added value of  6DOF robotic couch to  improve setup accuracy with 
the Cone Beam CTscanner (CBCT). The radiation therapist and techni-
cians were instructed to use the system and, through daily use, de-
termined the best application of the system. 
Results: Guckenberger et al. found a rotational error >2° in 3.7% of 
pelvic tumors, 26.4% of thoracic tumors and 12,4% of head and neck 
tumors; the corresponding maximal rotational errors were 5° , 8° and 
6°. Kaiser et al. observed in 96.6% of prostate and head and neck 
cancer a rotational correction <4°, with no difference between week 
1 and 4 of treatment; a smaller pitch variation but a larger yaw 
variation were recorded in head and neck. Concerning dosimetric 
results,  Guckenberger et al. observed a decreased target coverage 
and an highly increased dose to the organat at risk (OAR) when elon-
gated target volume and sharp dose gradients were adjacent to OAR. 
Lang et al. observed a reduction of target coverage for pitch of 3° 
with no differences between dorsal o ventral direction. In our centre 
from October to December 2012, 5 prostate and 3 H&N patients were 
enrolled. The magnitude of roll variation was  greater in both groups 
(mean (±SD) of -0.5±1.2° in prostate and a maximal value of 3.8° and 
a mean (±SD) of 1.3±1,2 ° in H&N with a maximal value of 3.4°). The 
pitch variations were greater for patients treated to the pelvis (means 
(±SD) of -0.4±1.1° vs -0.1±0.8° with a maximal value of 2.8° vs 1.9°), 
while the mean (±SD) interfractional yaw was 0.1±0.7° in prostate and 
0.0±0.6° in H&N patients. No correlation was observed between the 
magnitude of translational and rotational shift in either group. The 
online correction using CBCT studies added less than one minute to 
the treatment time when compared to IGRT without robotic 6DOF 
couch. 
Conclusions: These data confirm the relevance of rotational shift and 
the feasibility of using a robotic 6 DOFcorrection table in routine 
radiotherapy. In our centre correlation between volumetric and 
geometrical shift data and evaluation of its dosimetrical impact on 
adaptive dose is ongoing.  
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This presentation discusses an ongoing project lead by members of the 
ESTRO RTT Committee on the Development of guidelines for set up 
and verification requirements in head and neck radiotherapy.  This is 
the first set of ESTRO guideline to be developed by RTTs. 
The presentation will give the background as to why ESTRO develops 
guidelines for its members, the rationale for the selection of this topic 
and the progress to date. 
The methodology for the project includes an extended literature 
review, the development of an online questionnaire and its translation 
and distribution to RTTs throughout Europe as well as case reports 
from selected clinical departments across Europe. 
The results of the extended literature review will be presented, along 
with the preliminary results of the questionnaire and the focus of the 
case reports will be discussed.  
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Irradiation of bladder cancer is challenging since the variable and 
deformable bladder and bowel filling makes the target highly mobile. 
Traditionally, large target margins (up to several cm) are applied with 
the high dose area comprising the full range of bladder filling. Innova-
tions were enabled by the introduction of Cone Beam CT (CBCT) 
during the last decade.  
A challenge for image guided radiotherapy is that the tumor on the 
bladder wall is difficult to delineate on planning CT and not visible at 
all on CBCT. Several procedures are developed to demarcate the 
tumor, using cystoscopy. For instance, the contrast liquid lipiodol is 
successfully injected in the bladder wall to locate the tumor using a 
flexible scope. Lipiodol markers are well visible on CT for guiding 
target delineation. Moreover, markers are also visible on CBCT during 
the whole treatment course enabling daily target localization. 
The visibility of the target on CBCT in combination with a rather well 
visible bladder wall enabled application of adaptive radiotherapy 
(ART) procedures. Currently reported ART procedures are variations 
on the following scheme: 
 Acquisition of planning CTs with varying bladder filling (typically 
a full and empty bladder). 
 Creation of a number of 'additional bladders', with interpolated 
(or also extrapolated) volumes. 
 Design of plans-of-the-day (PDs) for each bladder volume. 
 Treatment with daily CBCT acquisition. 
 Patient repositioning, based on bony anatomy or tumor markers. 
 Based on the amount of bladder filling the correct PD is selected 
and delivered. 
This approach has shown to enable a significant reduction of the 
target margins and sparing of organs-at-risk like the small bowel and 
healthy part of the bladder. 
One of the challenges for clinical introduction of ART is the PD selec-
tion. This selection is based on the bladder volume. It is possible to 
automate the bladder delineation on CBCT. An approach with a 
'restricted bladder shape' has been investigated, fitting the shape on 
the grey value gradient of the CBCT image. As final check, the auto-
matically obtained bladder shape can be corrected manually. This 
approach turned out to be effective in selecting the correct PD and 
corresponds in 81% with the manually chosen PD.  
To report the actually given dose to each daily deformed target and 
bladder shape, the daily dose must be accumulated. It requires an 
anatomically correct deformable registration, defining the corres-
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pondence of each voxel with respect to the planning CT. The widely 
applied intensity-based algorithms operate globally on the whole 
image. They are not capable of accurately matching large heteroge-
neous deformations as occur in the bladder area.  
A number of feature-based approaches are used like the Finite Ele-
ment Method (FEM). The FEM describes the forces in the bladder and 
deforms the organs according to urine filling by solving the stress 
equations. Such models are in principle able to yield a good anatomi-
cal correspondence. However, for their best performance they require 
detailed knowledge of the tissue properties which is not yet available. 
A more heuristic approach can be followed by application of the 
Symmetric Thin Plate Spline Robust Point Matching algorithm. Points 
are placed on the surfaces of the volumes that have to be matched. 
Subsequently, the distances of these points are minimized. Recently, 
the algorithm is modified with a weight parameter to allow flexibility 
control of the tumor and bladder wall. They are considered as sepa-
rate structures, with a more flexible bladder. Rather coherent regis-
trations are achieved, with lower marker errors for the modified 
algorithm (Figure). 
It can be concluded that important progress has been made to effec-
tively improve bladder cancer irradiation. An important role is played 
by the cystoscopic guided tumor demarcation to visualize the tumor 
during treatment. Sparing of normal tissue is achieved by the adaptive 
procedures. Improvements have to be achieved for better practical 
support of clinical ART procedures and deformable image registration 
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By using the unique resources for conducting epidemiological research 
that we have in the Nordic countries, facilitated by the existence of 
nationwide population and health registries that can be accessed with 
unique individual identification numbers, several population-based, 
studies have been conducted within the Nordic countries to evaluate 
the impact of cancer therapy at a young age on the health of the 
patients and their offspring.  
Three different population-based, nationwide studies will be pre-
sented as examples of clinical epidemiological studies on late effects 
of childhood cancer with outcome data derived from health registries 
and a ‘gold standard’ approach being used for exposure assessment 
including organ radiation dosimetry: (1) A case–cohort study based on 
the population-based cohort of Danish childhood cancer patients and 
all their children with the purpose to quantify the extent to which 
cancer therapy contributes to genetic disease in the children of 
survivors including chromosomal abnormalities, congenital malforma-
tions, stillbirths, and neonatal deaths as possible indicators of genetic 
damage in the next generation. Preconception radiation doses to the 
gonads, uterus, and pituitary gland and administered chemotherapy 
have been quantified from medical records and related to adverse 
outcomes using a generalized estimating equation model and the 
results will be presented. (2) A greater international collaboration to 
study trans-generational effects of cancer treatment in children and 
adolescents – the Genetic Consequences of Cancer Treatment (GCCT) 
study - currently under way in Denmark, Finland and the USA with a 
similar design but with an increased sample size by adding the 
offspring of cancer survivors diagnosed in early adulthood in both 
Denmark and Finland (www.gcct.org). This study is expected to 
provide more definitive answers to questions about the integrity of 
the germline in human populations that have been exposed to muta-
genic cancer therapy. (3) A large ongoing Adult Life after Childhood 
Cancer in Scandinavia (ALiCCS; www.aliccs.org) study of late effects 
in childhood cancer patients. The Nordic cohort consists of nearly 
33,000 children and adolescents with cancer diagnosed below age 20 
in Denmark, Finland, Iceland, Norway, and Sweden. Morbidity-specific 
incidence and cause-specific mortality in these patients will be com-
pared with that of a combined Nordic cohort of more than 212,000 
population-based comparisons. In a cohort surveillance approach, the 
relative and absolute risks for different chronic diseases in adult 
survivors will be assessed based on discharge diagnoses in national 
patient registries. In the initial phase of this research initiative, 
priority is given to late effects in terms of cardiovascular and pulmo-
nary disorders, endocrine disorders and reproductive failures, 
and renal and gastrointestinal disorders. Based on the findings in this 
screening phase, specific, well-defined outcomes will be investigated 
in case-cohort studies among 5-year survivors in order to investigate 
associations, including dose-response, between specific treatment 
regimens and selected outcomes. Detailed information on chemothe-
rapy including drugs and doses and radiotherapy will be abstracted 
from medical records and for some of the studies organ radiation 
doses from direct and scattered irradiation will be estimated.  
The strengths of these studies include the unbiased ascertainment of 
cancer cases through a search in nationwide cancer registries, com-
plete identification of their children (for offspring studies) and un-
biased identification of population comparisons, and long-term, 
virtually complete follow-up of all study populations. 
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Adverse effects of cancer treatment (normal tissue damage, new 
malignancies) represent well-studied phenomena across the radiation 
disciplines. Novel steps are needed to fully exploit current technical 
opportunities to avoid normal tissue radiation exposure. Pediatric 
oncology represents a good model to illustrate the proposed ap-
proaches. On average pediatric cancer patients have a better progno-
sis than adults, they are exposed to radiotherapy and chemotherapy in 
vulnerable periods of growth and development, treatment field 
delineation can be challenging due to close proximity of surrounding 
organs in small children, and these patients are at potential risk for a 
variety of health problems at different points in their life span.  Valid 
dose effect studies require accurate characterization of radiation dose 
characteristics combined with complete and accurate follow-up for 
health effects, including uniform definitions for such health outcomes. 
 In the past, collaborative groups of pediatric oncologists, epidemiolo-
gists, and radiation oncologists have initiated large observational 
follow-up studies of cancer survivors, to quantify dose effect relation-
ships for chemotherapy and radiotherapy. The professionals who treat 
childhood cancer patients typically follow trial protocols, thus allow-
ing for large, often international, trial based late effects follow up 
studies. These studies seemingly represent rather separate, parallel 
efforts, often using different terminology but seeking answers to 
closely related or identical questions. From a methodologic perspec-
tive, trial based follow-up efforts are based on excellent dose assess-
ment methods but face challenges in achieving uniform and complete 
health outcome follow-up beyond 10 or even 5 yrs post treatment. 
Conversely, observational retrospective follow-up studies typically 
have reasonable or good health outcome data, currently on average 
spanning 30+ yrs of follow-up for the oldest pediatric cancer survivors, 
however, it has remained challenging to accurately describe doses at 
organs at risk according to the standards common (and expected) in 
clinical radiation oncology.  In essence, we need to combine the dose 
estimation standard from clinical trials with the follow-up methods 
applied in observational studies. Several parallel approaches should 
